Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AFMD NASDAQ:BYSI NASDAQ:NLTX NASDAQ:SPPI NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAFMDAffimed$0.18-34.9%$0.28$0.07▼$5.84$2.92M2.074.68 million shs22.99 million shsBYSIBeyondSpring$2.25-2.6%$2.13$0.98▼$3.44$90.71M0.1732,141 shs6,300 shsNLTXNeoleukin Therapeutics$21.26+4.8%$18.04$2.03▼$14.36$199.80M1.1150,104 shs229,155 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AVKTXViking Therapeutics$31.29+2.9%$27.53$18.92▼$81.73$3.51B0.624.06 million shs3.25 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAFMDAffimed0.00%0.00%0.00%-71.01%-96.38%BYSIBeyondSpring+4.52%+0.87%+4.52%+111.93%-0.43%NLTXNeoleukin Therapeutics+4.00%+5.68%-7.10%+124.58%-44.88%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics+0.70%+9.67%+10.26%+41.26%-43.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAFMDAffimed2.9449 of 5 stars4.00.00.04.30.60.01.3BYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum Pharmaceuticals0.5293 of 5 stars0.00.00.04.70.60.00.6VKTXViking Therapeutics3.9852 of 5 stars3.51.00.04.72.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAFMDAffimed 2.00Hold$3.621,895.87% UpsideBYSIBeyondSpring 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ASPPISpectrum Pharmaceuticals 0.00N/AN/AN/AVKTXViking Therapeutics 3.00Buy$87.15178.54% UpsideCurrent Analyst Ratings BreakdownLatest AFMD, VKTX, BYSI, NLTX, and SPPI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.005/14/2025AFMDAffimedCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2025AFMDAffimedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/13/2025AFMDAffimedLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025AFMDAffimedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.105/13/2025AFMDAffimedLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.394/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAFMDAffimed$877K3.33N/AN/A$4.19 per share0.04BYSIBeyondSpringN/AN/AN/AN/A($0.37) per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87VKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAFMDAffimed-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)BYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-14.41%-14.02%7/23/2025 (Estimated)Latest AFMD, VKTX, BYSI, NLTX, and SPPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025VKTXViking Therapeutics-$0.44N/AN/AN/AN/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAFMDAffimedN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAFMDAffimed0.131.931.93BYSIBeyondSpringN/A2.492.49NLTXNeoleukin TherapeuticsN/A15.3315.33SPPISpectrum PharmaceuticalsN/A2.712.38VKTXViking TherapeuticsN/A44.2544.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAFMDAffimed30.82%BYSIBeyondSpring40.29%NLTXNeoleukin Therapeutics52.37%SPPISpectrum Pharmaceuticals21.67%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipAFMDAffimed3.80%BYSIBeyondSpring29.31%NLTXNeoleukin Therapeutics1.58%SPPISpectrum Pharmaceuticals2.70%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAFMDAffimed20016.10 million15.49 millionOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableVKTXViking Therapeutics20112.31 million107.71 millionOptionableAFMD, VKTX, BYSI, NLTX, and SPPI HeadlinesRecent News About These CompaniesViking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts2 hours ago | zacks.comU.S. Capital Wealth Advisors LLC Sells 8,423 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)July 10 at 5:26 AM | marketbeat.comViking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial ResultsJuly 9 at 4:17 PM | insidermonkey.comFinancial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)July 9 at 5:41 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?July 8 at 4:24 PM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.July 8 at 3:24 AM | marketbeat.comBetter Growth Buy: Eli Lilly vs. Viking TherapeuticsJuly 7 at 3:45 AM | fool.comAugust 22nd Options Now Available For Viking Therapeutics (VKTX)July 5, 2025 | nasdaq.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of StockJuly 4, 2025 | insidertrades.comWhy I Think Viking Therapeutics Is an Asymmetric Growth OpportunityJuly 4, 2025 | fool.comViking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key FactsJuly 3, 2025 | zacks.comInsider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of StockJuly 3, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells $118,466.82 in StockJuly 3, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) CEO Sells 26,889 SharesJuly 3, 2025 | marketbeat.comVKTX - Viking Therapeutics Inc Sustainability - MorningstarJuly 3, 2025 | morningstar.comMH.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)July 2, 2025 | theglobeandmail.comViking Therapeutics (NASDAQ:VKTX) Shares Up 7.7% - Here's What HappenedJuly 2, 2025 | marketbeat.comIs Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?July 2, 2025 | zacks.comGot $200? 2 Biotech Stocks to Buy and Hold ForeverJuly 1, 2025 | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by BrokeragesJuly 1, 2025 | marketbeat.com3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking...June 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingAFMD, VKTX, BYSI, NLTX, and SPPI Company DescriptionsAffimed NASDAQ:AFMD$0.18 -0.10 (-34.95%) As of 05/19/2025Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.BeyondSpring NASDAQ:BYSI$2.28 -0.04 (-1.52%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Neoleukin Therapeutics NASDAQ:NLTX$21.26 +0.98 (+4.83%) As of 07/9/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Viking Therapeutics NASDAQ:VKTX$31.29 +0.89 (+2.93%) Closing price 04:00 PM EasternExtended Trading$31.35 +0.06 (+0.19%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
